Related Experiment Video
Updated: Sep 28, 2026

Synthesis and Assay of Vibrio Quorum Sensing Inhibitors
Published on: May 31, 2024
Children as a special population at risk--quinolones as an example for xenobiotics exhibiting skeletal toxicity
1Department of Toxicology, Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, Garystrasse 5, 14195 Berlin, Germany. ralf.stahlmann@medizin.fu-berlin.de
Insights
Immature mammals are highly sensitive to quinolone toxicity, which can cause cartilage and bone damage. This developmental toxicity is linked to the drug's magnesium-chelating properties, affecting young animals most severely.
Area of Science:
- Toxicology
- Developmental Biology
- Pharmacology
Background:
- The developing skeletal system in mammals exhibits unique sensitivities to xenobiotics.
- Quinolones are a class of xenobiotics known to cause toxicity, particularly affecting cartilage, bone growth, and tendons.
Purpose of the Study:
- To discuss the sensitivity of the immature skeletal system to xenobiotics, using quinolones as a case study.
- To examine the developmental stage-dependent toxicity of quinolones on cartilage, bone, and tendons.
Main Methods:
- Review of workshop discussions on regulatory toxicology and sensitive subgroups.
- Analysis of animal experiments (dogs and rats) investigating quinolone effects at various developmental stages.
- Consideration of clinical and experimental data on quinolone-induced tendopathies.
Main Results:
- Chondrotoxicity of quinolones is dependent on the developmental stage, with peak sensitivity observed in young animals (e.g., 3-6 month old dogs, 3-6 week old rats).
- Mature articular cartilage is not a target for quinolone toxicity.
- Quinolones can damage the epiphyseal growth plate in early development, leading to irreversible bone damage and growth inhibition.
- Tendopathies are another manifestation, with susceptibility in juveniles versus adults being unclear.
Conclusions:
- The immature mammalian skeletal system is particularly vulnerable to quinolone-induced toxicity.
- Developmental stage is a critical factor in quinolone toxicity, affecting cartilage, bone, and potentially tendons.
- The magnesium-chelating properties of quinolones are implicated in the pathogenesis of these toxic effects, possibly involving radical formation and connective tissue damage.
Abstract:
The sensitivity of the immature skeletal system during postnatal mammalian development was discussed during the workshop "Children as a Sensitive Subgroup and their Role in Regulatory Toxicology" (Schwenk et al. 2002, Arch Toxicol, in press). As a typical example of xenobiotics exhibiting this extraordinary type of toxicity, the quinolone-induced effects on cartilage, bone growth, and tendons were considered in depth. Animal experiments indicate that chondrotoxicity of quinolones can affect articular cartilage depending on the developmental stage. Results from studies with pipemidic acid in dogs at various developmental stages from 1 week old to 17 months old showed pronounced effects in the most sensitive age groups: 3- to 6-month-old dogs exhibited gait alterations and lameness, but signs of toxicity were not observed in 12- or 17-month-old dogs. Similarly, experiments performed in rats indicate that they exhibit the highest sensitivity for articular cartilage defects at a certain stage of development between 3 and 6 weeks postnatally; mature articular cartilage does not seem to be a target for quinolone-induced toxicity. Some very limited data indicate that in animals at an early developmental phase the epiphyseal growth plate can also be damaged by quinolones, and that these effects are associated with irreversible bone damage and growth inhibition. Another manifestation of toxic effects of quinolones on connective tissue structures are tendopathies. For this effect, it is not quite clear whether juveniles are more susceptible than adults because clinical and experimental data seem to point in different directions. Pathogenesis of both effects can probably be explained by the magnesium-chelating properties of these drugs, leading to a deficit of functionally available magnesium and, subsequently, to radical formation and irreversible connective tissue lesions. However, unequivocal explanations for the phase-dependency of the effects are lacking.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Toxicity: Risk factors